![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C23H28F2N2O4S |
Molar mass | 466.54 g·mol−1 |
3D model ( JSmol) | |
| |
|
Suntinorexton ( INN ) is an experimental orexin receptor agonist. [1] It acts as a selective agonist of the orexin OX2 receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company. [2]
Proposed INN: List 123
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C23H28F2N2O4S |
Molar mass | 466.54 g·mol−1 |
3D model ( JSmol) | |
| |
|
Suntinorexton ( INN ) is an experimental orexin receptor agonist. [1] It acts as a selective agonist of the orexin OX2 receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company. [2]
Proposed INN: List 123